Conclusions
1 evidence topic · 15 sources
Summary
An estimated 60,480 U.S. cases of oral cavity and pharynx cancer will be diagnosed in 2026; no source counts HPV-negative recurrent or metastatic HNSCC. Bicara states that about 80% of recurrent or metastatic HNSCC is HPV-negative, while 258 of U.S. real-world first-line pembrolizumab recipients (39.9%) had HPV-negative tumors; their median real-world overall survival was 9 months on pembrolizumab monotherapy and 7 months with chemotherapy (20 and 15 months with HPV-positive tumors). In KEYNOTE-048, the response rate with pembrolizumab alone was 19.1% (CPS ≥1), and 71.7% of participants receiving pembrolizumab-chemotherapy had grade ≥3 treatment-related adverse events.
All ficerafusp alfa results come from BCA101X1101, an open-label, single-arm phase 1/1b trial with investigator-assessed response. In HPV-negative participants of the 1500 mg weekly cohort (20 March 2025 snapshot), the confirmed objective response rate was 54% (15 of 28), median progression-free survival 9.9 months, and median overall survival 21.3 months; the 3-year overall survival rate was 31% at the 31 March 2026 cut. Of 42 participants, 19 (45%) had grade 3 treatment-related adverse events and 32 (76%) acneiform dermatitis. HPV-negative cohorts had 27 to 30 evaluable participants, patient-reported outcomes were not assessed, and KEYNOTE-048 comparisons are cross-trial.
FORTIFI-HN01 (NCT06788990), a double-blind, first-line phase 2/3 trial of about 650 participants, randomizes 2:1 in phase 3 to ficerafusp alfa 1500 mg weekly or placebo, each with pembrolizumab; primary endpoints are objective response rate by blinded independent central review (BICR) at an interim analysis and overall survival at the final analysis. It enrolls recurrent or metastatic HNSCC of the oral cavity, hypopharynx, larynx, or oropharynx, “with documented HPV-negative disease if presenting with OPSCC”; HPV testing applies to oropharyngeal tumors alone, and nasopharyngeal and paranasal sinus primaries are excluded. It requires PD-L1 CPS ≥1 and no prior systemic therapy for recurrent or metastatic disease, with multimodal systemic therapy completed more than 6 months earlier. The sources differ: the EU record requires HPV documentation “per central testing” and 22C3 PD-L1 testing, neither specified in the ClinicalTrials.gov record; BICR-assessed measurable disease appears in the EU record and the 2025 abstract alone; and the quoted EU anti-EGFR exclusion has no exception for radiosensitizing treatment.
The FDA granted Breakthrough Therapy Designation for CPS ≥1 disease “excluding human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma.” Bicara expects interim results in mid-2027 to support accelerated approval, and a potential U.S. launch in 2028. No price, randomized result, cost-effectiveness analysis, or health technology assessment exists; ficerafusp alfa would be added to pembrolizumab ($12,517.44 per 3-week dose).
Items to revisit after the interim analysis:
- BICR-assessed response, its durability, and overall survival against placebo plus pembrolizumab.
- Dermatologic, bleeding, and anemia events under randomized comparison.
- The labeled population, HPV test, and PD-L1 assay.
- The dosing regimen (FORTIFI-FLEX tests every-3-week maintenance) and the price.